EPHB6: A Potential Drug Target for Neurodegenerative Disorders

Target Name: EPHB6

NCBI ID: G2051

EPHB6

EPHB6: A Potential Drug Target for Neurodegenerative Disorders

EPHB6 (EPHB6_HUMAN), a transmembrane protein that belongs to the EPH receptor tyrosine kinase family, is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The EPH receptor tyrosine kinase family is a family of transmembrane proteins that play a crucial role in the development and maintenance of the optic nerve and retina. The EPHB6 protein is a member of this family and is expressed in various tissues and organs, including the brain, eye, and tissues.

EPHB6 has been shown to be involved in several physiological processes, including cell signaling, angiogenesis, and tissue repair. It has also been implicated in the development and progression of several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the key functions of EPHB6 is its role in cell signaling. EPHB6 has been shown to play a role in the regulation of cell proliferation, differentiation, and survival. It has been shown to promote cell survival by inhibiting cell suicide, and it has also been shown to promote cell growth by activating cell signaling pathways.

EPHB6 has also been shown to be involved in the regulation of angiogenesis, the process by which new blood vessels are formed. It has been shown to promote angiogenesis by activating angiogenic signaling pathways and inhibiting anti-angiogenic signaling pathways.

In addition to its role in cell signaling and angiogenesis, EPHB6 has also been implicated in the development and progression of several diseases. For example, it has been shown to be involved in the development of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has also been shown to be involved in the development of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis.

Given the potential involvement of EPHB6 in several diseases, it is a promising target for drug development. Researchers have been exploring the use of small molecules and other compounds to inhibit or activate EPHB6, with the goal of developing treatments for neurodegenerative disorders, cancer, and autoimmune diseases.

In conclusion, EPHB6 is a transmembrane protein that is involved in several physiological processes and has been implicated in the development and progression of several diseases. As a potential drug target and biomarker, EPHB6 is a promising target for the development of new treatments for neurodegenerative disorders, cancer, and autoimmune diseases. Further research is needed to fully understand the role of EPHB6 in these diseases and to develop effective treatments.

Protein Name: EPH Receptor B6

Functions: Kinase-defective receptor for members of the ephrin-B family. Binds to ephrin-B1 and ephrin-B2. Modulates cell adhesion and migration by exerting both positive and negative effects upon stimulation with ephrin-B2. Inhibits JNK activation, T-cell receptor-induced IL-2 secretion and CD25 expression upon stimulation with ephrin-B2

The "EPHB6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPHB6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets